Skip to content

Excimer Lamp Versus Excimer Laser in Vitiligo Treatment

Comparative Study of 308nm Excimer Lamp and 308nm Excimer Laser in the Treatment of Vitiligo

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00696358
Enrollment
Unknown
Registered
2008-06-12
Start date
Unknown
Completion date
Unknown
Last updated
2008-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitiligo

Keywords

Vitiligo

Brief summary

308 nm excimer lamp and 308 nm excimer laser have both provide interesting results in treating vitiligo. They have the same wavelength but the type of emission of the photons is different. To date there is no direct comparative data concerning these two devices in this indication. The aim of the study is to make an intra-individual prospective comparison between these two phototherapies.

Interventions

RADIATION308nm excimer lamp

50 mJ/cm² below the MED (minimal erythemal dose) and progressive increase Twice a week for 12 weeks

50 mJ/cm² below the MED (minimal erythemal dose) and progressive increase Twice a week for 12 weeks (same doses will be used between the 2 arms)

Sponsors

Centre Hospitalier Universitaire de Nice
Lead SponsorOTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patient above 18 * vitiligo for more than 3 months * at least 2 vitiligo symmetric patches more than 10cm² * to read and understand the inform consent * to have a social security number * non pregnant for women

Exclusion criteria

* pregnant women * keloids * history of radiotherapy or skin cancer in the treated areas * treatment for vitiligo in the past 4 weeks * phototherapy in the past 12 weeks; history of photodermatosis * treatment inducing photosensibilization * immunosuppression * patient who participated in a study in the past 3 months

Design outcomes

Primary

MeasureTime frame
Repigmentation rate in the treated areas12 weeks

Secondary

MeasureTime frame
Tolerance and safety of the treatments12 weeks

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026